A potential therapeutic hepatitis C treatment can be manufactured using E. coli to express one of the hepatitis C proteins via recombinant DNA technology. The hepatitis C protein is derived from the hepatitis C virus genome and is used to stimulate the patient’s own immune system to attack the virus without exposure to the intact virus. Explain how you can create a strain of E. coli that will produce the therapeutic protein using the following materials: plasmid, restriction enzyme, DNA ligase, hepatitis C virus DNA.

First, one has to use a restriction enzyme to cut the hepatitis C virus DNA from the hepatitis C virus genome and the plasmid of the E. coli. Second, one has to add the gene from the hepatitis C virus genome, which allows the creation of the hepatitis protein, to the plasmid of the E. coli, which has to also be cut by a restriction enzyme to allow the gene from the virusgenometobeaddedtotheE.coliplasmid. Last,onehastoaddDNAligasetotheequationtorepairthesugarphosphatebonds

Technorati Tags: dna ligase, e coli, hepatitis, hepatitis c, hepatitis c treatment, hepatitis c virus, immune system, intact virus, protein, proteins, recombinant dna technology, restriction enzyme, virus dna, virus genome